company background image

Cassava Sciences NasdaqCM:SAVA Stock Report

Last Price


Market Cap







09 Aug, 2022


Company Financials +
SAVA fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health6/6

SAVA Stock Overview

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Cassava Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cassava Sciences
Historical stock prices
Current Share PriceUS$20.21
52 Week HighUS$126.51
52 Week LowUS$13.84
1 Month Change-16.76%
3 Month Change17.36%
1 Year Change-81.39%
3 Year Change1,543.09%
5 Year Change514.27%
Change since IPO-86.80%

Recent News & Updates

Aug 03

Cassava Sciences GAAP EPS of -$0.48 misses by $0.06

Cassava Sciences press release (NASDAQ:SAVA): Q2 GAAP EPS of -$0.48 misses by $0.06. Cash Position - $197.2 Million of Cash and Cash Equivalents at June 30, 2022. Cognition Maintenance Study - Completion of Patient Enrollment is Expected Q4 2022. Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies.

Aug 03
We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

We're Hopeful That Cassava Sciences (NASDAQ:SAVA) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Jul 27

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

The shares of clinical-stage biotech Cassava Sciences (NASDAQ:SAVA) crashed ~44% in the pre-market after Reuters reported on Wednesday that the U.S. Justice Department had opened a criminal investigation linked to its experimental Alzheimer’s therapy simufilam. The investigation deals with whether the Texas-based biotech manipulated research results for simufilam, the news agency said, citing two people familiar with the inquiry. The Justice Department officials handling the probe are specialized in investigating whether companies or individuals have misled or defrauded multiple parties, including investors, or government agencies, The probe, similar to any other investigation conducted by the Justice Department, could lead to criminal charges or close without any charges being brought against the company. Kate Watson Moss, a lawyer for Cassava (SAVA), refused to comment on the ongoing probe. "To be clear: Cassava Sciences vehemently denies any and all allegations of wrongdoing," Watson Moss noted, adding that the firm "has never been charged with a crime, and for good reason - Cassava Sciences has never engaged in criminal conduct."

Jun 10

Cassava Sciences And Alzheimer's Disease: A Precipitious Path

One probably should not invest in Cassava Sciences until all investigations are completed. Alternative mechanisms of action exist that better explain Cassava Sciences' trial results than the one offered by the company. Short-term catalysts may have some effect on Cassava Sciences' stock value but the key to the company's success (or failure) are results from two phase three clinical trials. Better treatments for Alzheimer's Disease likely exist.

Shareholder Returns

SAVAUS PharmaceuticalsUS Market

Return vs Industry: SAVA underperformed the US Pharmaceuticals industry which returned 2% over the past year.

Return vs Market: SAVA underperformed the US Market which returned -13% over the past year.

Price Volatility

Is SAVA's price volatile compared to industry and market?
SAVA volatility
SAVA Average Weekly Movement15.1%
Pharmaceuticals Industry Average Movement11.8%
Market Average Movement7.9%
10% most volatile stocks in US Market17.1%
10% least volatile stocks in US Market3.2%

Stable Share Price: SAVA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: SAVA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

199824Remi Barbier

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

Cassava Sciences, Inc. Fundamentals Summary

How do Cassava Sciences's earnings and revenue compare to its market cap?
SAVA fundamental statistics
Market CapUS$810.38m
Earnings (TTM)-US$60.59m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SAVA income statement (TTM)
Cost of RevenueUS$50.24m
Gross Profit-US$50.24m
Other ExpensesUS$10.35m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-1.51
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did SAVA perform over the long term?

See historical performance and comparison